HCI is HIMSS' first EMRAM education provider

The HCI Group, a healthcare IT services consultancy, is HIMSS' first official Electronic Medical Record Adoption Model (EMRAM) Global Education provider.

HIMSS Analytics has been providing maturity models for more than 10 years, focusing on important areas of healthcare advancement including the EMRAM. The model is used globally as a measurement of the maturity of healthcare facilities as they leverage technology to improve the quality of healthcare.

As a HIMSS global EMRAM Education partner, HCI will provide client education and consulting to improve EMR Adoption Model scores and prepare those clients for HIMSS Analytics validation as Stage 6 and Stage 7 organizations on the world scale.

“Embarking on this educator program partnership will help HCI further our mission of being the global leader in healthcare technology consulting,” said Ricky Caplin, CEO of the HCI Group. “It also allows us to become expert partners with HIMSS Analytics and support the values brought by EMR adoption.”

“Leveraging an EMR, whether you buy or build, is more than just getting rid of the paper; it is a cultural paradigm shift and a transformation of care,” added Anthony Binge, International Managing Director, the HCI Groups. “Technology is but an enabler; to be successful you must truly grasp the organizational and cultural change that needs to take place through every level of every department.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.